You are here

  • Home
  • Online First
  • Vulnerability of patients on immunosuppressive therapy to SARS-CoV-2 reinfection

Article Text

Article menu
Download PDFPDF
Letter
Vulnerability of patients on immunosuppressive therapy to SARS-CoV-2 reinfection
  1. Yashdeep Singh Pathania
  1. Department of Dermatology, Venereology and Leprology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
  1. Correspondence to Dr Yashdeep Singh Pathania, Department of Dermatology, Venereology and Leprology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India; yashdeepsinghpathania{at}gmail.com

https://doi.org/10.1136/bmjspcare-2021-003260

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    To the Editor,

    The catastrophe by the novel COVID-19 has still not come to a halt in the world. There is an upsurge of COVID-19 cases and also SARS-CoV-2 reinfections or reactivations. Protective immunity following SARS-CoV-2 infection is uncertain. There are incidences of SARS-CoV-2 reinfection in patients who were on immunosuppressive therapy for other diseases. Immunosuppression in COVID-19 is a double-edged sword. It may be detrimental in the initial course of COVID-19, but may be life-saving with regard to alleviating the cytokine storm in the later course of the disease. However, it has resulted in a surge of cases of SARS-CoV-2 reinfection throughout the world.

    Few viral infections provide lifelong immunity after the first infection, but seasonal coronaviruses provide short-lived protective immunity. Reinfections are expected to occur …

    View Full Text

    Footnotes

    • Contributors YSP prepared and finalised the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.